Novo Nordisk stock heads into the open after a 7.7 percent drop

At the close on September 21, 2026, Novo Nordisk stock had fallen 7.7 percent in Copenhagen as its Capital Markets Day targets failed to reassure investors. The company is continuing its strategy event today.

Novo Nordisk stock closed 7.7 percent lower in Copenhagen on September 21, 2026, after the company presented new long-term strategic ambitions at its Capital Markets Day. The decline followed a strategy update that set a 2026 to 2030 revenue growth target in line with industry peers.

September 21, 2026 in numbers

Novo Nordisk A/S (ISIN DK0060534915) ended at DKK 307.30 on Nasdaq Copenhagen on September 21, 2026, according to CNBC, which reported the 7.7 percent decline. The US-listed ADR closed at USD 39.80, down 7.96 percent, on the same date, according to Yahoo Finance data.

At its Capital Markets Day, CNBC reported that Novo aims to launch more than five multi-blockbuster medicines by 2030 and generate more than DKK 150 billion in risk-adjusted pipeline sales by 2035. The company also said its 2026 to 2030 revenue growth should track industry peers.

Capital Markets Day continues today

Novo is continuing its Capital Markets Day on September 22, 2026, after publishing strategic ambitions for its pipeline, research and development, commercial operations and manufacturing. Yahoo Finance reported that presentations and webcast materials are being made available through the event.